ZIOPHARM Oncology (ZIOP) And Intrexon (XON)
Jan 27, 2015 - The therapy is expected to be a game changer in the cancer immunotherapy landscape.
GERMANTOWN, Md., BOSTON, and HOUSTON, Jan. 13, 2015 /PRNewswire/ -- Intrexon Corporation (XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (ZIOP), today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property deveoped at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Less
ZIOPHARM Oncology Upgraded to “Outperform” at BMO Capital Markets
January 14th, 2015 - 0 comments - Filed Under - by John Miller
ZIOPHARM Oncology logoZIOPHARM Oncology (NASDAQ:ZIOP) was upgraded by stock analysts at BMO Capital Markets from a “market perform” rating to an “outperform” rating in a report issued on Wednesday.The firm raises to $15.00 price target on the stock,
see u there !
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015 BY Adam Feuerstein Follow |
01/06/15 - 08:30 AM EST
Bluebird Bio's (BLUE) gene therapy cures sickle cell disease. Or, new clinical data presented this year suggest strongly that this will happen in the near future.
Beyond The Ice Bucket Challenge"NurOwn" Could Become The First Real Treatment for ALS
By Maya Yarowsky and Anouk Lone
ALS patients around the world are looking towards NurOwn for what will hopefully become the first long-lasting treatment for their debilitating condition.
Pre-Market Most Active for Dec 30,2014 CVEO,VALE,ARCP,NDRM
By Nasdaq News
08:39:53 AM EST
As reported by Zack's, the current mean recommendation for NDRM is " strong buy "
CART stocks $$